DMB Clinical Trials

Size	Price	Qty
5mg	USD 197
25mg	USD 497

Clinical Trials

Several clinical trials are currently evaluating the therapeutic applications and metabolic impacts of this compound across conditions including type 2 diabetes mellitus, Alzheimer's disease, and cancer-related chemotherapy effects, taste disorders, and malnutrition. Ranging from Phase 2 and Phase 3 evaluations to unphased assessments, these studies vary in status between completed and actively recruiting. Trial sponsors encompass academic, commercial, and corporate entities, including the Instituto de Investigación Hospital Universitario La Paz, Bigespas LTD, and Société des Produits Nestlé.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07251023	RECRUITING	Alzheimer Type Dementia	Bigespas LTD	2025-11-20	PHASE3
NCT06292351	COMPLETED	Alzheimer Disease; Dementia of Alzheimer Type	Bigespas LTD	2023-12-27	PHASE2
NCT05486260	COMPLETED	Cancer; Dysgeusia; Hypogeusia; Ageusia; Chemotherapy Effect; Malnutrition	Instituto de Investigación Hospital Universitario La Paz	2022-06-23
NCT04413357	COMPLETED	Diabetes Mellitus, Type 2	Société des Produits Nestlé (SPN)	2020-05-18

(data from https://clinicaltrials.gov, updated on 2025-12-10)

Check the DMB product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

DMB selectively binds to and activates the glucagon-like peptide-1 receptor by forming hydrogen bonds with Tyr42, Cys71, and Ser84 residues, initiating downstream signaling cascades that suppress cellular apoptosis. This receptor activation and cytoprotective mechanism mitigate focal cerebral ischemic injury, demonstrating therapeutic relevance to metabolic and neurodegenerative trial conditions including type 2 diabetes mellitus and Alzheimer's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).